Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Can we overcome the 'clinico-radiological paradox' in multiple sclerosis?
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Cyclophosphamide for multiple sclerosis.
Rehabilitation in transverse myelitis.
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod.
Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation.
Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel.
Progressive multifocal leukoencephalopathy: new concepts.
Immunopathology of multiple sclerosis.
Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
Endogeneous Remyelination: Findings in Human Studies.
B-Cell Depletion Abrogates T Cell-Mediated Demyelination in an Antibody-Nondependent Common Marmoset Experimental Autoimmune Encephalomyelitis Model.
Neurorehabilitation for other neurologic disorders.
Autonomic dysfunction: A unifying multiple sclerosis theory, linking chronic cerebrospinal venous insufficiency, vitamin D(3), and Epstein-Barr virus.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.
Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.
Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Correction: Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
The next generation of exoskeletons: lighter, cheaper devices are in the works.

Pages